|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...280281282283284285286287288289290...10661067» |
- Darzalex (daratumumab) / J&J
Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX () - Aug 13, 2022 - Abstract #IMW2022IMW_496;
Post hoc analyses of CASTOR and POLLUX, both individually and pooled, showed that the addition of DARA to standard-of-care regimens prolonged PFS across many RRMM subgroups, including patients with high-risk disease, after a >6-year median follow-up. These results support the use of DARA-containing regimens in RRMM patients across clinically relevant subgroups.
- Sarclisa (isatuximab-irfc) / Sanofi
Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONAMM first interim analysis () - Aug 13, 2022 - Abstract #IMW2022IMW_494;
P=N/A
Both Isa-Pd and Isa-Kd have a manageable safety profile in routine clinical practice. These data provide RWE to support the use of Isa in RRMM outside of clinical trials and in wider populations.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM () - Aug 13, 2022 - Abstract #IMW2022IMW_493;
P3
Secondary endpoints include overall survival, duration of response, time to progression, overall response rate, minimal residual disease negativity rate, safety, and quality of life. Enrollment is expected to begin in Q2 2022.
- Sarclisa (isatuximab-irfc) / Sanofi
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study () - Aug 13, 2022 - Abstract #IMW2022IMW_491;
Despite a few differences in study populations, similar mPFS in IMAGE and ICARIA-MM support Isa-Pd as a standard of care for RRMM. This is the first study to report meaningful PFS for Isa-Pd among pts at first relapse suggesting that Isa-Pd is a potential new treatment option in earlier lines of therapy.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Impact of adjusting bortezomib dose in the pomalidomide, bortezomib, and dexamethasone (PVd) combination: a post hoc analysis of the OPTIMISMM study () - Aug 13, 2022 - Abstract #IMW2022IMW_489;
Longer and more continuous PVd Tx, with fewer Tx discontinuations, appears to be more important for efficacy than receiving the full BORT dose. Selection bias was possible as pts without an adjustment may have progressed early and pts on Tx longer were more likely to have an adjustment.
- Ninlaro (ixazomib) / Takeda, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_488;
An amendment allowed for subcutaneous daratumumab. The quadruplet regimen DIPd is a well-tolerated combination that has shown early safety, efficacy, and high ORR for patients with R/R MM, and appears beneficial for patients with high-risk genetic abnormalities
- Ninlaro (ixazomib) / Takeda
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in 295 Japanese patients with relapsed/refractory multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_484;
In this real-world study, pts receiving IRd were frailer, older, more heavily treated and with a lower RDI than pts included in clinical trials. These results suggest that IRd therapy is an effective and tolerable treatment option in realworld settings outside of clinical trials.
- Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_483;
These data demonstrate an educational need regarding the latest developments in the treatment of RRMM. They also demonstrate that online, case-based CME/NCPD–approved activities can result in statistically significant improvements in clinicians’ knowledge of therapeutic advances and management of treatment-related adverse events for patients with RRMM.
- Darzalex (daratumumab) / J&J
Real-world outcomes in multiple myeloma (MM) patients who received subsequent therapy after daratumumab from the PREAMBLE study () - Aug 13, 2022 - Abstract #IMW2022IMW_481;
Elo combinations remain potent treatment options after Dara and patients are as likely to see a PFS benefit when receiving Elo combinations as when receiving all other standard of care. Elo-treated patients are also as likely to see a PFS benefit whether they’ve previously received Dara or not.
- Empliciti (elotuzumab) / AbbVie, BMS
Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis () - Aug 13, 2022 - Abstract #IMW2022IMW_480;
There exist two distinct, separate networks in 3L+ MM; those with pomalidomide + dex (Pd) as a control arm; daratumumab + pomalidomide + dex (DPd), isatuximab + pomalidomide + dex (IsaPd), pomalidomide + cyclophosphamide + dex (PCd) and those with a bortezomib + dex (Vd) control arm; daratumumab + bortezomib + dex (DVd), venetoclax + bortezomib + dex (VenVd), Selinexor + bortezomib + dex (SVd)...The main inclusion and exclusion criteria were similar, except for the inclusion of patients refractory to lenalidomide and for the inclusion of patients having one prior line of therapy... Evidence suggests that EloPd is effective in improving PFS and OS in patients with RRMM when compared with other established and new regimens.
- lenalidomide / Generic mfg.
Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database () - Aug 13, 2022 - Abstract #IMW2022IMW_477;
This analysis demonstrates that PI-exposed, lenalidomide-refractory patients have poor PFS and move quickly through available therapies, regardless of the number of PL. These data suggest the need for new, effective, and safe treatment regimens for this patient population.
- lenalidomide / Generic mfg.
Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database () - Aug 13, 2022 - Abstract #IMW2022IMW_476;
Despite many available treatment options, patients who have received 1–3 PL, are PI- and IMiD-exposed, and lenalidomide-refractory progress quickly through currently available therapies, and survival outcomes remain poor. This population-based analysis demonstrates the absence of a clear standard of care for this difficult-to-treat, older, comorbid patient population, and it suggests the need for new and effective treatment regimens, as well as multidisciplinary supportive care.
- carfilzomib / Generic mfg.
Clinical impact of time to the best response in relapsed/refractory multiple myeloma patients receiving carfilzomib () - Aug 13, 2022 - Abstract #IMW2022IMW_474;
Our data demonstrated a significant correlation between time to the best response and survival outcomes in carfilzomib-treated patients with RRMM. The gradual response to the therapy was a favorable prognostic factor for survival outcomes independent of high-risk features, type of previous treatment, and the treatment response.
- Darzalex (daratumumab) / J&J
Real-world treatment patterns and clinical outcomes in patients with triple-class exposed relapsed or refractory multiple myeloma in United States clinical practice () - Aug 13, 2022 - Abstract #IMW2022IMW_473;
Results show that patients with TCE RRMM cycle through various treatment regimens and have poor survival and clinical outcomes. These RW results highlight the need for highly effective treatments; emerging novel therapies may improve outcomes in patients with TCE RRMM.
- lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Addition of carfilzomib as a third agent in lenalidomiderefractory multiple myeloma: switching from doublet to triplet () - Aug 13, 2022 - Abstract #IMW2022IMW_472;
ISS was equally distributed, and all patients had previously been treated with bortezomib and IMIDs, and were refractory to this agents...Carfilzomib was well tolerated, with grade 2 anemia in 39%(16/41) of patients, successfully managed by ESAs, without necessity of blood transfusions; 29% (12/41) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis was given, no ospedalization was required, no septic shocks were observed); 34% (14/41) grade 2, 21% (9/41) grade 3 and 12% (5/41) grade 4 thrombocytopenia, without hemorrhagic events and transfusion-dependency... Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and it could be considered as a bridge to a second autologous or allogenic SCT.
- bortezomib / Generic mfg., bendamustine / Generic mfg.
Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomibdexamethasone (BVD) in novel agents’ era () - Aug 13, 2022 - Abstract #IMW2022IMW_471;
Thus, aiming to provide further insights in this field, also in novel agents’era, we present here a retrospective, real-life analysis of patients with relapsed/refractory MM (rrMM), who had received salvage therapy with bendamustine in combination with bortezomib and dexamethasone (BVD)...36-82), median age at start of treatment 63.6 years (r.37-86) treated with several lines of treatments (median 6, r. 2-11), every refractory to all the drugs previously received (also Bortezomib), received BVD (B 90 mg/sqm days 1,2; V 1.3 mg/sqm days 1,4,8,11, D 20 mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression...Eight patients have surprisingly achieved a notable PR after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide). The triplet Bendamustine-BortezomibDexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT, also after failure of novel agents.
- Blenrep (belantamab mafodotin) / GSK
Real-world belantamab mafodotin (belamaf) use: a US retrospective longitudinal pharmacy and medical opensource claims database assessment () - Aug 13, 2022 - Abstract #IMW2022IMW_470;
Real-world evidence from this study suggests belamaf use in clinical practice is generally consistent with the label indication and managed with dose reductions and holds, and patients remain on therapy consistent with the DREAMM-2 trial. Ongoing belamaf studies are examining alternative dosing schedules and combinations to further optimize use.
- Darzalex (daratumumab) / J&J
Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: a safety analysis of the phase 2 MM-014 study () - Aug 13, 2022 - Abstract #IMW2022IMW_468;
P2
There was no evidence of cumulative toxicity between LEN and POM, and pts with dose modification had a higher mPFS than the overall cohort. Managing AEs through dose modification may improve outcomes for pts with RRMM treated with DPd.
- iberdomide (CC-220) / BMS
Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial () - Aug 13, 2022 - Abstract #IMW2022IMW_467;
P1b/2a
Across all cohorts, a >20% difference in dose was needed for meaningful change in IBER exposure, immune PD began to saturate at doses ≥1.0mg, and decreases in tumor burden were greatest at the 1.6mg dose. Based on these results, 1.0, 1.3, and 1.6mg of IBER were chosen for dose optimization of IberDd for RRMM, and 0.75, 1.0, and 1.3mg were selected for dose optimization of IBER monotherapy in the newly diagnosed MM maintenance setting.
- mezigdomide (BMS-986348) / BMS
Preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib () - Aug 13, 2022 - Abstract #IMW2022IMW_466;
P1/2, P1b/
Translational studies indicate that proteasome inhibition does not abrogate MEZI pharmacodynamic activity, with the 1.0 mg dose appearing to be the most active. Further exploration of doses between 0.3 and 1.0 mg in combination with either BORT or CFZ are suggested to determine the optimal dose.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China () - Aug 13, 2022 - Abstract #IMW2022IMW_462;
VRD regimen has promising efficacy and result in a substantial survival benefit. Autologous stem cell transplantation (ASCT) after VRD induction therapy is associated with higher rate of deep response, lower rate of undetectable MRD and longer survival.
- thalidomide / Generic mfg.
The optimal dose of thalidomide on the treatment of newly diagnosed multiple myeloma: real-world experience in Taiwan () - Aug 13, 2022 - Abstract #IMW2022IMW_461;
By adjusting the dose of thalidomide, we can greatly reduce the adverse events of VTD regimen. Because thalidomide 50 mg per day is still an effective treatment for newly diagnosed myeloma, it is unnecessary to abandon VTD regimen if the patient is unable to tolerate thalidomide 100 mg per day due to toxicities.
- Ninlaro (ixazomib) / Takeda
A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients () - Aug 13, 2022 - Abstract #IMW2022IMW_458;
The ORR after induction was 87%. TRM is 2%.
- Darzalex (daratumumab) / J&J
Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN () - Aug 13, 2022 - Abstract #IMW2022IMW_456;
After 2 years of maintenance in the GRIFFIN study, Black pts continued to derive clinical benefit from the addition of DARA to RVd frontline treatment and Black pts did not have an increase in adverse events. Larger studies are needed to confirm this benefit.
- Darzalex (daratumumab) / J&J
First line daratumumab-VTd versus VRd for transplant eligible multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_454;
The current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet induction regimens (daratumumab plus bortezomib-thalidomide-dexamethasone; DVTd). Our study supports front-line quadruple induction regimen containing CD38 monoclonal antibody for transplant-eligible newly diagnosed multiple myeloma.
- Darzalex (daratumumab) / J&J, Mozobil (plerixafor) / Sanofi
D-VTd as induction therapy in newly diagnosed multiple myeloma (NDMM) patients who are candidates for transplantation: a real-life experience in a single center () - Aug 13, 2022 - Abstract #IMW2022IMW_452;
D-VTd as induction therapy in NDMM transplant-eligible patients is feasible in real-life practice with a very high response rate and acceptable toxicity. Our results are in line with those of the Cassiopeia clinical trial, highlighting the rapid response and the high rate of negative minimal residual disease (MRD).
- Busulfan plus cyclophosphamide and etoposide versus highdose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_451;
Between March 2016 and September 2021, patients aged 47-67 (median 57 years) with multiple myeloma were enrolled to receive bortezomib, thalidomide and dexamethasone induction followed by ASCT. Our study showed that BuCyE is an effective and well-tolerated alternative to HDMEL conditioning, with good PFS.
- bortezomib / Generic mfg.
Efficacy and safety of bortezomib in once weekly vs. twice weekly dosing in the treatment of multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_450;
Introduction: The combination of lenalidomide (R), bortezomib (V), and dexamethasone (D) (RVD) has been the standard of care for multiple myeloma since the publication of the SWOG S0777 trial in 2017. In RVD induction, weekly bortezomib has similar efficacy to twice weekly, with numerically lower incidence of all grade PN and PN related dose-reductions.
- Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Trial () - Aug 13, 2022 - Abstract #IMW2022IMW_443;
NDMM patients receiving RCyBorD induction maintain serological vaccine responses against Wuhan and Omicron variants. Our findings support ongoing vaccination through therapy to maintain and improve protection against SARS-CoV-2 variants, particularly Omicron, in NDMM patients.
- Ninlaro (ixazomib) / Takeda
In-class transition (iCT) from parenteral bortezomib to oral ixazomib therapy in newly diagnosed multiple myeloma (NDMM) patients (pts): fully accrued data from the community-based US MM-6 study () - Aug 13, 2022 - Abstract #IMW2022IMW_441;
P4
The AE profile of IRd was similar to previous clinical reports. No adverse impact on QoL/treatment satisfaction was observed.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD) () - Aug 13, 2022 - Abstract #IMW2022IMW_440;
Older age and presence of plasmacytomas at diagnosis were non-modifiable risk factors for both EM and ED. Stage or renal function did not have an impact in EM or ED in VRD-treated NDMM.
- Machine learning-assisted identification of optimal first-line treatment for newly diagnosed, transplant ineligible multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_439;
In conclusion, we used the machine learning models to stratify the transplant ineligible NDMM into the high and low risk subgroups with respect to use of VMP or RD chemotherapy as the first-line treatment. A total of 10 clinical characteristics measured during diagnosis are needed as inputs to the trained models, which we plan to validate in a prospective study.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Solitary pulmonary plasmacytoma: about a case () - Aug 13, 2022 - Abstract #IMW2022IMW_437;
We reported a case of solitary pulmonary plasmacytoma that was initially diagnosed as lung cancer. Although standard treatments for solitary plasmocytomas usually encompasses surgery and/or radiotherapy, we started a systemic therapy with VRD because of the size and its extensive tumor infiltration, without any complications.
- Darzalex (daratumumab) / J&J
Real-world duration of use and dosing frequency of daratumumab in patients with multiple myeloma in the U.S. () - Aug 13, 2022 - Abstract #IMW2022IMW_436;
Patients initiating DARA remain on the therapy for a median of 16.6 months with one-sixth continuing DARA beyond 3 years. The dosing frequency observed in the realworld was consistent with the approved label.
- Ninlaro (ixazomib) / Takeda
In-class transition (iCT) from bortezomib (V)-based induction to oral ixazomib-lenalidomide-dexamethasone vs parenteral V-based therapy: comparative effectiveness in newly diagnosed multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_433;
P4
NDMM pts who transitioned to IRd following 3 cycles of V-based induction in US MM-6 had a significantly higher ORR and longer DOT compared with INSIGHT MM pts who continued to receive V-based therapy. Thus, iCT from Vbased therapy to all-oral IRd may improve outcomes in NDMM pts compared with continued V-based therapy.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Lenalidomide, bortezomib, and dexamethasone (RVd) as firstline (1L) therapy in patients who are non-transplanted: results from the Connect® MM registry () - Aug 13, 2022 - Abstract #IMW2022IMW_432;
Blood. 2021;138 (suppl1):3782) indicating RVd is effective across age groups.
- Darzalex (daratumumab) / J&J
Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen () - Aug 13, 2022 - Abstract #IMW2022IMW_427;
Longer f/u and serial scans may show increased rates of remineralization with continued therapy. In addition, antiresorptive therapy may improve remineralization rates in these pts, further supporting studies in bone anabolic agents targeting sclerostin or other pathways that may enhance bone healing and decrease SRE risk.
- dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Domestic opportunity in heavily pretreated multiple myeloma not eligible to hospital-based treatment: role of pomalidomide-dexamethasone () - Aug 13, 2022 - Abstract #IMW2022IMW_422;
52-86), and median age at start of treatment 76 years (r.56-90) treated with several lines of treatments (median 7, r. 2-11), every refractory to all the drugs previously received (also Bortezomib, Thalidomide and Lenalidomide), received Pomalidomide-Dexamethasone (Pomalidomide 4 mg for 21 days, Dexamethasone 40 mg days 1,8,15,22, pegfilgrastim day +8) every 28 days, until progression. Pomalidomide-dexamethasone has shown significant efficacy and a very good compliance, thanks to oral administration, in a particularly severe setting of heavily pretreated patients, relapsed and refractory to all available therapeutic resources, also after failure of novel agents.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone () - Aug 13, 2022 - Abstract #IMW2022IMW_421;
Pomalidomide-dexamethasone has shown significant efficacy and a very good compliance, thanks to oral administration, in a particularly severe setting of heavily pretreated patients, relapsed and refractory to all available therapeutic resources, also after failure of novel agents. In patients affected by heavily pretreated MM treated with pomalidomide-dexamethasone, pegfilgrastim seems to reduce the incidence of severe neutropenia and infections and may increase the possibility to maintain the scheduled time of treatment.
- Empliciti (elotuzumab) / AbbVie, BMS, Darzalex (daratumumab) / J&J
Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience () - Aug 13, 2022 - Abstract #IMW2022IMW_402;
Novel agent therapies were safe, and no death case occurred on therapy. Future studies are needed to clarify the optimal sequence of novel agents and the best combination.
- Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_397;
Our data indicate that SARS-CoV-2 infection in “triple vaccinated” MM patients is quite frequent, but also that the clinical outcome of COVID-19 appears to be significantly improved by a “booster” dose of vaccine with respect to pre-vaccination era in this high risk population. The role of new antiviral agents and monoclonal antibodies currently used to reduce the risk of progression of COVID-19 to severe disease warrants to be further investigated in larger series.
- iberdomide (CC-220) / BMS
Iberdomide induces activation and proliferation of innate and adaptive immune cell subsets in the tumor microenvironment of relapsed/refractory myeloma patients () - Aug 13, 2022 - Abstract #IMW2022IMW_332;
Our data demonstrate that iberdomide leads to strong and rapid immunomodulatory effects of innate and adaptive immunity. This data establishes rational combination strategies for iberdomide with other immuneenhancing therapies in RRMM.
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd) () - Aug 13, 2022 - Abstract #IMW2022IMW_329;
The GEM-CLARIDEX trial was leveraged to identify immune biomarkers in 186 newly diagnosed transplantineligible MM patients treated with Rd (+/- clarithromycin) until disease progression. This study shows the clinical value of immune profiling at diagnosis and identifies immune cell populations predictive both of survival and of fatal infections in elderly MM patients treated with the backbone regimen Rd.
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_322;
scRNA sequencing of the BM granulocytic lineage after induction treatment consisting of carfilzomib, lenalidomide and dexamethasone with or without an anti-CD38 monoclonal antibody (n=5) demonstrated that mature neutrophils maintained an activated transcriptome including elevated levels of BAFF. These data reveal a stromal-neutrophil axis aimed at cultivating a pro-tumor micro-environment by increased production of plasma cell survival factor BAFF downstream of iMSC-derived signals.
- sotatercept (MK-7962) / BMS, Merck (MSD)
Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_284;
P1
Preliminary data from this study suggest that sotatercept increases both hgb and BMD. Anemia and bone disease are significant causes of morbidity in MM, and sotatercept is one of the first agents acting on the microenvironment that may simultaneously address both problems.
- Darzalex (daratumumab) / J&J
Successful use of frontline daratumumab lenalidomide and dexamethasone in transplant ineligible frail patients with moderate renal failure at the time of presentation () - Aug 13, 2022 - Abstract #IMW2022IMW_270;
Thrombo-prophylaxis was uniformly done by Apixaban 2.5 mg twice daily and all patients received trimethoprim-sulfamethoxazole and valacyclovir. DRd combination was able to induce hematological and renal responses even in patients who were extremely elderly, frail and having restricted renal functions with manageable adverse events.
- Darzalex (daratumumab) / J&J
Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction () - Aug 13, 2022 - Abstract #IMW2022IMW_265;
We can conclude that, the safety data is scarce regarding the overweight and obese patients who receive D. Especially in patients who needs a higher dose of D because of morbid obesity we do not have a good idea of IRR incidence. In patients who are overweight or obese or suffering from a COPD, a split first dose application of D should be regarded as a safer alternative and possibly should be regarded as a standard of care approach with further trials designed to address this need.
- cyclophosphamide / Generic mfg.
Intensity of cyclophosphamide-based bridging regimens before BCMA-directed CAR-T therapy () - Aug 13, 2022 - Abstract #IMW2022IMW_264;
Overall, IV_ddCy did not significantly prolong vein-to-vein intervals but was associated with delayed platelet recovery and a worsened survival signal. Study limitations include small sample size and confounding from measures of MM aggressiveness among patients who received IV_ddCy bridging, for example rates of EMD.
- Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma () - Aug 13, 2022 - Abstract #IMW2022IMW_248;
However, the responses appear to be less durable with median PFS of only 23 weeks. Additional follow up with commercial ide-cel use in the real-world is needed to validate these results.
- | dexamethasone injection / Generic mfg.
Journal: Possible errors in the article "Potential benefits of salvage intratympanic dexamethasone injection in profound idiopathic sudden sensorineural hearing loss". (Pubmed Central) - Aug 13, 2022
Additional follow up with commercial ide-cel use in the real-world is needed to validate these results. No abstract available